Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026)
Rapport Therapeutics' (RAPP) quarterly Depreciation & Amortization (CF) came in at $227000.0 in Q1 2026, down 6.97% year-on-year from $244000.0 in Q1 2025, and down 14.34% on a QoQ basis from $265000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Depreciation & Amortization (CF) data on file, last reported at $227000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 6.97% year-over-year to $227000.0 in Q1 2026; TTM through Mar 2026 was $1.0 million, a 7.41% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 21.22% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $227000.0, down from $265000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for RAPP reached as high as $265000.0 in Q4 2025 and fell as low as $23000.0 in Q3 2023.
- Historically, Depreciation & Amortization (CF) has averaged $188250.0 across 4 years, with a median of $223000.0 in 2024.
- Across the five-year window, Depreciation & Amortization (CF) surged 852.17% in 2024 and declined 6.97% in 2026, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $53000.0 in 2023, then soared by 390.57% to $260000.0 in 2024, then grew by 1.92% to $265000.0 in 2025, then slipped by 14.34% to $227000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $227000.0 in Q1 2026, $265000.0 in Q4 2025, and $256000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - | 227,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 265,000.00 |
| Dec 31, 2025 | 265,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Dec 31, 2024 | 260,000.00 |
| Dec 31, 2024 | 260,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Jun 30, 2024 | 208,000.00 |
| Jun 30, 2024 | 208,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Dec 31, 2023 | 53,000.00 |